RARE | Ticker Profile - Titan Protect

RARE

Ultragenyx Pharmaceutical Inc.

Healthcare · Biotechnology · NMS

$21.91

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

24.23

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.2%

Year-over-year revenue change

Profit Margin

-90.9%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$48.00

+119% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 19 analysts covering this stock

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

https://www.ultragenyx.com

Country: United States Employees: 1,371 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.100

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0184

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.320

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-22.0%

Historical annualised return based on price data

Max Drawdown

-68.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.39

Very low correlation to market moves

52W High

$42.37

48% below the year high

52W Low

$18.29

20% above the year low

Avg Volume

1,882,945

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.7%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-6.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

2.02

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.65

Like current ratio but excludes inventory — stricter test

Gross Margin

-28.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-102.2%

Profit from core operations before interest and tax

Free Cash Flow

$-219,090,000

Negative — the business is spending more than it generates

Revenue (TTM)

$670M

Total revenue over the last 12 months

Net Income

$-609,000,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$96.00

Target Median

$48.00

Target Low

$25.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go